Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 3,480,000 shares, an increase of 446.6% from the May 15th total of 636,700 shares. Approximately 6.7% of the shares of the company are sold short. Based on an average trading volume of 3,760,000 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Spero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Anson Funds Management LP increased its stake in Spero Therapeutics by 98.9% in the first quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock valued at $5,500,000 after purchasing an additional 3,798,932 shares during the period. Mackenzie Financial Corp raised its stake in Spero Therapeutics by 11.4% during the 1st quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock valued at $151,000 after acquiring an additional 21,472 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Spero Therapeutics during the 4th quarter worth approximately $57,000. Jane Street Group LLC purchased a new position in shares of Spero Therapeutics in the 4th quarter valued at approximately $54,000. Finally, Three Seasons Wealth LLC acquired a new position in shares of Spero Therapeutics in the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 25.60% of the company's stock.

Spero Therapeutics Stock Performance

Shares of SPRO stock traded down $0.06 during mid-day trading on Friday, hitting $2.83. 2,070,735 shares of the stock were exchanged, compared to its average volume of 1,149,408. The stock's fifty day simple moving average is $1.18 and its two-hundred day simple moving average is $0.99. Spero Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.06. The stock has a market capitalization of $158.23 million, a price-to-earnings ratio of 40.43 and a beta of 1.31.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.30. The firm had revenue of $5.87 million for the quarter, compared to the consensus estimate of $11.00 million. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%. On average, research analysts expect that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.